- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04072198
Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR)
Phase II Study on NIVolumab in Combination With FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced COloRectal Cancer RASm/BRAFm Patients
This is a multicentric single arm, open label trial. In this study patients candidated to a first line of chemotherapy for metastatic colorectal cancer will be treated with 8 cycles of folfoxiri plus bevacizumab plus nivolumab followed by a maintenance with bevacizumab plus nivolumab.
Patients who do not progress during chemotherapy phase will receive bevacizumab plus nivolumab as maintenance therapy.
Patients will be treated until disease progression, unacceptable toxicity or patient/physician decision.
연구 개요
상태
정황
상세 설명
This is a prospective, open-label, multicentric phase II trial in which patients with metastatic colorectal cancer RASm/BRAFm patients will receive nivolumab in combination with FOLFOXIRI/Bevacizumab as first line chemotherapy.
Study screening will take place within 28 days prior to initiation of study treatment. At screening, every patient must have local RAS/BRAF known status. A centralized review of RAS/BRAF status will be performed during the study.
Eligible patients will be enrolled and begin treatment with FOLFOXIRI/bevacizumab plus nivolumab every 2 weeks for 8 cycles followed by maintenance with bevacizumab plus nivolumab every 2 weeks until disease progression, unacceptable toxicity or patient/physician decision. Bevacizumab will be administered intravenously at dose of 5 mg/kg every 2 weeks. Nivolumab will be administered intravenously at flat dose of 240 mg every 2 weeks.
Folfoxiri will be administered as 165 mg/m2 intravenous infusion of irinotecan for 60 min, followed by an 85 mg/m2 intravenous infusion of oxaliplatin given concurrently with leucovorin at a dose of 200 mg/m2 for 120 min, followed by a 3200 mg/m2 continuous infusion of fluorouracil for 48 h.
During the study treatment period, patients will be followed for safety based on AE assessments including vital signs, physical findings and clinical laboratory test results.
In order to guarantee the safety of the patients, the enrolment will be stopped when the 10th patient will start treatment. An Independent Monitoring Committee will evaluate the safety data of these patients and will decide if the study should be completed, amended or closed.
Efficacy will be evaluated by the investigator according to RECIST v1.1 every 8 weeks during treatment and then every 3 months for 3 years.
During the study baseline tumor blocks will be centrally analysed to determinate inflammatory infiltrate, MSI/MSS and PD-L1 status. The biological characterization and Tumor Mutation Burden (TMB) will be also analysed centrally.
Following discontinuation of study treatment, safety assessments will be conducted 30 days after the last study drug administration or until initiation of other anti-cancer therapy (whichever occurs first). Thereafter, patients will be followed for disease progression (unless this has already occurred), SAEs, anticancer therapy and survival. Follow-up will continue for up to 3 years.
A blood sample will be collected for all patients at baseline, prior to cycle 5, at the end of chemotherapy and at disease progression.
Quality of life will be assessed at baseline, every 4 weeks during treatment and study discontinuation visit.
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Annalisa Berselli, BD
- 전화번호: +390522295181
- 이메일: annalisa.berselli@ausl.re.it
연구 장소
-
-
-
Brescia, 이탈리아
- 모병
- Istituto Ospedaliero Fondazione Poliambulanza
-
연락하다:
- Alberto Zaniboni
-
Catania, 이탈리아
- 모병
- ARNAS Garibaldi
-
연락하다:
- Roberto Bordonaro
-
Firenze, 이탈리아
- 모병
- Azienda Ospedaliero-Universitaria Careggi
-
Napoli, 이탈리아
- 모병
- Istituto Nazionale Tumori Fondazione G.Pascale
-
연락하다:
- Guglielmo Nasti
-
Padova, 이탈리아
- 모병
- Istituto Oncologico Veneto
-
연락하다:
- Francesca Bergamo
-
Reggio Emilia, 이탈리아
- 모병
- AUSL/IRCCS di Reggio Emilia
-
연락하다:
- Carmine Pinto, MD
-
Roma, 이탈리아
- 모병
- Policlinico Universitario Campus Bio-Medico
-
연락하다:
- Giuseppe Tonini
-
San Giovanni Rotondo, 이탈리아
- 모병
- IRCCS - Casa Sollievo della Sofferenza
-
연락하다:
- Evaristo Maiello
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Written informed consent.
- Male or female of 18-75 years of age on day of signing informed consent.
- Histologically confirmed diagnosis of colorectal cancer RAS/BRAF mutated.
- Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease.
- Patients suitable for first line chemotherapy.
- Life expectancy > 3 months.
- At least one site of measurable disease per RECIST criteria.
- Performance status of 0-1 on the ECOG Performance Scale.
- Adequate organ function
- Availability at baseline of a representative formalin-fixed, paraffin-embedded (FFPE) diagnostic tumor specimen, as primary and/or metastatic tumor tissue block or as fifteen 5-micron unstained slides are allowed (the neoplastic cell content of each tumor sample will be assessed and in those cases with neoplastic cells <50% a macro-dissection of the specimen will be performed, if possible).
- If DPD status is known it must be wild type. No restriction are applied if DPD status in unknown.
- Women of childbearing potential must have a negative blood pregnancy test within 24 hr prior to the start of study drug. For this trial, women of childbearing potential are defined as all women after puberty, unless they are postmenopausal for at least 12 months, are surgically sterile, or are sexually inactive.
- Subjects and their partners must be willing to avoid pregnancy during the trial and until 5 months for WOCBP (Women of Childbearing Potential) and 7 months for male subjects with female partners of WOCBP after the last trial treatment. Male subjects with female partners of childbearing potential and female subjects of childbearing potential must, therefore, be willing to use adequate contraception as approved by the investigator (barriers contraceptive measure or oral contraception).
Exclusion Criteria:
- Prior chemotherapy, excluded patient treated in neo/adjuvant setting at least 12 months before diagnosis of metastatic disease.
- Radiotherapy to any site within 4 weeks before the study.
- Serious, non-healing wound, ulcer, or bone fracture.
- Evidence of bleeding diathesis or coagulopathy.
- Uncontrolled hypertension and prior history of hypertensive crisis or hypertensive encephalopathy.
- Systemic corticosteroids within 2 weeks of the first dose of nivolumab.
- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment.
- Additional malignancy in the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Active and untreated brain (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are not using steroids for at least 7 days prior to trial treatment.
- Any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (> 10 mg daily prednisone equivalent) or immunosuppressive medications except for syndromes which would not be expected to recur in the absence of an external trigger.
- Evidence of interstitial lung disease, active non-infectious pneumonitis, or a history of grade 3 or greater pneumonitis.
- Active infection requiring systemic therapy.
- History of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection.
- Live vaccine within 30 days prior to the first dose of trial treatment.
- Chronic, daily treatment with high-dose aspirin (>325 mg/day).
- Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months of study enrolment.
- Any previous venous thromboembolism > NCI CTCAE Grade 3.
- History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to the first study treatment.
- Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study.
- Presence of colic prosthesis or stent.
- History of any severe hypersensitivity reactions to any monoclonal antibody.
- Women of childbearing potential who are pregnant or breastfeeding.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: FOLFOXIRI/Bevacizumab + Nivolumab
Bevacizumab 5 mg/m2 Nivolumab 240 mg Irinotecan 165 mg/m2 iv (max 8 cycles) Oxaliplatin + leucovorin 200 mg/m2 (max 8 cycles) Fluorouracil 3200 mg/m2 (max 8 cycles)
|
240 mg every 2 weeks for 8 cycles followed by maintenance
5 mg/kg every 2 weeks for 8 cycles followed by maintenance
165 mg/m2 every 2 weeks for 8 cycles
85 mg/m2 every 2 weeks for 8 cycles
200 mg/m2 every 2 weeks for 8 cycles
3200mg/m2 every 2 weeks for 8 cycles
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
ORR
기간: 36 months
|
To demonstrate that adding nivolumab to standard colorectal first line chemotherapy improves the Overall Response Rate as determinated using RECIST 1.1 criteria
|
36 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Safety of combination
기간: 36 months
|
Safety assessments will include the incidence, nature, and severity of Adverse Events (AEs)
|
36 months
|
OS
기간: 36 months
|
Evaluate the efficacy in terms of overall survival (OS) defined as the time from start of study drug to the date of death from any cause
|
36 months
|
TTP
기간: 36 months
|
To evaluate the Time To Progression (TTP) defined as the time between the date of start of study drug and the first date of documented progression, based on investigator assessment (as per RECIST 1.1 criteria), or death due to any cause, whichever occurs first
|
36 months
|
Duration of response
기간: 36 months
|
To evaluate the duration of response defined as the time between the date of first evidence of response (SD/PR/CR) and the date of documented progression or death due to any cause, whichever occurs first
|
36 months
|
Quality of life with QLQ-C30 questionnaire
기간: 36 months
|
To evaluate the quality of life of patients determinated with questionnaire
|
36 months
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Damato A, Bergamo F, Antonuzzo L, Nasti G, Iachetta F, Romagnani A, Gervasi E, Larocca M, Pinto C. FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial. Front Oncol. 2021 Dec 14;11:766500. doi: 10.3389/fonc.2021.766500. eCollection 2021.
- Damato A, Iachetta F, Antonuzzo L, Nasti G, Bergamo F, Bordonaro R, Maiello E, Zaniboni A, Tonini G, Romagnani A, Berselli A, Normanno N, Pinto C. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). BMC Cancer. 2020 Aug 31;20(1):822. doi: 10.1186/s12885-020-07268-4.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- GOIRC-03-2018
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
대장암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)모집하지 않고 적극적으로III기 전립선 선암종 AJCC v7 | II기 전립선 선암종 AJCC v7 | 1기 전립선 선암종 American Joint Committee on Cancer(AJCC) v7미국
Nivolumab에 대한 임상 시험
-
Universitätsklinikum KölnZKS Köln빼는자궁경부암 ≥ FIGO IIB 및/또는 림프절 전이
-
NYU Langone Health종료됨
-
Institut BergoniéBristol-Myers Squibb모병
-
St. Petersburg State Pavlov Medical University완전한
-
Stichting Hemato-Oncologie voor Volwassenen Nederland모집하지 않고 적극적으로림프종, B세포 | 비호지킨 림프종 | 고급 B 세포 림프종 | MYC 전위 | BCL-2 전좌네덜란드, 벨기에
-
M.D. Anderson Cancer Center모집하지 않고 적극적으로
-
Gruppo Oncologico del Nord-Ovest완전한
-
Amgen모병흑색종이탈리아, 스페인, 남아프리카, 일본, 세르비아, 보스니아 헤르체고비나, 미국, 아르헨티나, 칠레, 그루지야, 말레이시아, 대한민국, 프랑스, 독일, 네덜란드, 크로아티아, 태국, 브라질, 대만, 루마니아, 멕시코, 인도